Company Update (NYSEMKT:ATNM): Actinium Pharmaceuticals Inc Issues Letter to Shareholders Outlining Measures to Move Iomab-B and Actimab-A Into Advanced Development

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has it has issued a letter to shareholders providing an update on the progress it has made to advance its two drug candidates, Iomab-B and Actimab-A, towards commercialization. With a substantially stronger balance sheet following financing activity that yielded cash in excess of $25 million at June 30, 2015, the Company is well positioned to propel forward its research activities and transition its key programs with Iomab-B and Actimab-A through value creating milestones.

Highlights of the letter include:

  • Successfully completed the third cohort of AML (Acute Myeloid Leukemia) patients in Phase 1/2 trial for Actimab-A, in which patients received two doses of Actimab-A at 1.5 μCi/kg per dose compared to a lower dose of 1.0 μCi/kg that patients received in Cohort 2. Two out of three Actimab-A treated patients achieved complete remission in Cohort 3, with different degrees of hematological recovery (CRi). By comparison, one patient achieved Cri in Cohort 2.
  • Launched the enrollment process for Cohort 4 for Actimab-A and activated more medical centers to facilitate patient enrollment. With encouraging results observed as Phase 1 progressed, the Company anticipates strong support from this network as it enrolls patients for Phase 2.
  • Resolved an unexpected manufacturing problem through increased oversight of the production process. This has also generated valuable intellectual property, know-how and trade secrets that will further protect the Iomab-B process.
  • Submitted a request to the FDA (Food and Drug Administration) for a pre-IND meeting for Iomab-B. The FDA typically responds within 60 days of receiving an application.  Ramped up business development efforts to find suitable partners for both products to support their development and future commercial launch. (Original Source)

Shares of Actinium Pharmaceuticals opened today at $1.73 and are currently trading up at $1.9177. ATNM has a 1-year high of $8.12 and a 1-year low of $1.52. The stock’s 50-day moving average is $2.46 and its 200-day moving average is $3.05.

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts